chitosan and plga microspheres as drug delivery ... - UniCA Eprints

More documents

Recommendations

Info

2. Chitosan And PLGAdichloromethane and methanol) where the second component is used to increase theconcentration of drug in the dispersed phase. Hydrophobic drugs often present less of achallenge to formulate in slowly degradable microparticle systems, relative to hydrophilicdrugs, as they are often soluble in the organic solvents used, but are insoluble in water. Manyhydrophobicdrugs that have been encapsulated in biodegradable microparticles include (242).For example taxol has been successively encapsulated in PLGA microparticles with highefficiency (> 90%) (242, 243, 244). The maximum amount of drug encapsulated in themicroparticles typically depends on its solubility in the organic solvent used in theformulation. Taxol is now a common anticancer agent used against a wide variety of solidtumors including breast and ovarian cancers. It is insoluble in water and has a limitedsolubility in ethanol. Taxol has been encapsulated in PLGA microparticles of varying LA/GAratios using very simple O/W emulsions (244). The authors used dichloromethane as thesolvent for both PLGA (mol wt: 10,000) and taxol. A 4% gelatin solution was used as thecontinuous phase with simple mechanical mixing. An encapsulation efficiency of 98% frommicroparticles with an average diameter of 30 µm was achieved using 75:25 PLGA with noadditional additives. The in vitro release displayed a slow-sustained release of taxol with noinitial burst. In fact, the release was so slow that isopropyl myristate was added to change themicroparticle matrix to allow the formation of channels that would allow for faster diffusionof taxol from the microparticle. These results are not unexpected considering the hydrophobicnature of the drug and the immiscible nature of the solvents used for both phases of theemulsion. Thermodynamically, taxol must remain solvated in the dichloromethane untilwhich time the solvent is completely removed and, thus, the drug is homogeneouslyencapsulated in the newly formed microparticle. Because the release of taxol from PLGAmicroparticles is typically quite slow, the most significant obstacle in formulating thesemicroparticles is obtaining a sustained release of therapeutic levels of drug. Thus, additivessuch as isopropyl myristate, sucrose, and the use of PLGAs of varying molecular weight andhydrolytic degradation rates have been investigated as a means of accelerating the release oftaxol (244, 245).This biodegradable polymer can be successfully used as controlled delivery systems for manytype of drugs and for different route of administration. These systems could provide sustainedrelease of macromolecules ranging from a few days to several months, which avoid the dailymultiple administration. Furthermore, encapsulation in polymer matrix also protects labilemolecules from the degradation by enzymes. The application of these controlled delivery46
2. Chitosan And PLGAsystems result in numerous products in the market. These products all base on polyesterPLGA due to the favorable regulatory status of the polymer.47
Page 1: European Union Ministero dell’Uni
Page 5 and 6: Table Of Contents1. GENERAL INTRODU
Page 7: 7.1.4. Release Studies/Stability St
Page 10 and 11: 1. General Introduction1.1. Pulmona
Page 12 and 13: 1. General Introductionmucosa, and
Page 14 and 15: 1. General Introductionis the fact
Page 16 and 17: 1.3. Lung Anatomy1. General Introdu
Page 18 and 19: 1. General Introductionhighly vascu
Page 20 and 21: 201. General Introductionliquid (84
Page 22 and 23: 1. General IntroductionAerosol size
Page 24 and 25: 1. General Introductionof numerous
Page 26 and 27: 1. General Introductionintermittent
Page 28 and 29: 1. General Introductionsphere prepa
Page 30 and 31: 1. General Introductionit, respecti
Page 32 and 33: 1. General Introductionthe subject
Page 34 and 35: 1. General IntroductionA. zahoor et
Page 36 and 37: 2. Chitosan And PLGA2.1. Chitosan a
Page 38 and 39: 2. Chitosan And PLGAfor the prepara
Page 40 and 41: 2. Chitosan And PLGAmainly controll
Page 42 and 43: 2. Chitosan And PLGAAt present, a n
Page 44 and 45: 2. Chitosan And PLGAneed to be a go
Page 49 and 50: 3. Aim of the Work49
Page 51: 3. Aim of the WorkBiodegradable mic
Page 54 and 55: 4. RFP Loaded Chitosan Microspheres
Page 71 and 72: 5. Rifampicin Loaded ChitosanMicros
Page 83: 5. RFP Loaded Chitosan Microspheres
Page 86 and 87: 6. RFP Loaded PLGA Microspheres Pre
Page 96 and 97:
6. RFP Loaded PLGA Microspheres Pre
Page 98 and 99:
6. RFP Loaded PLGA Microspheres Pre
Page 100 and 101:
100
Page 102 and 103:
7. RFP Loaded PLGA Coated Chitosan
Page 104 and 105:
Page 106 and 107:
Page 108 and 109:
Page 110 and 111:
Page 112 and 113:
Page 114 and 115:
Page 116 and 117:
Page 118 and 119:
118
Page 120 and 121:
8. Final Discussion and Conclusions
Page 122 and 123:
9. References9. References1. Fred S
Page 124 and 125:
9. References40. Wayne L.G., Good R
Page 126 and 127:
1269. References88. Carpenter R.L.
Page 128 and 129:
1289. References135. Fukushima S.;
Page 130 and 131:
9. References173. Zeng X.M., Martin
Page 132 and 133:
9. References219. Berthold A., Crem
Page 134:
9. Referencesmediates target gene e
show all

chitosan and plga microspheres as drug delivery ... - UniCA Eprints

Create successful ePaper yourself

Delete template?

Save as template?